Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Bevacizumab (Avastin®) - SMC 1135/16 - in progress. (Indication: in combination with paclitaxel and cisplatin in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix).

Blinatumomab (Blincyto®) - SMC 1145/16 - Formulary Group decision will be published by 6th July 2016. (Indication: for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL)).

Budesonide (Budenofalk®) - SMC 1043/15Formulary Group decision will be published by 6th July 2016. (Indication: for the treatment of autoimmune hepatitis in non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis).

Co-careldopa (Duodopa®) - SMC 316/06 Formulary Group decision will be published by 6th July 2016. (Indication: for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results in patients not eligible for deep brain stimulation).

Febuxostat (Adenuric®) - SMC 1153/16 - Formulary Group decision will be published by 6th July 2016. (Indication: for the prevention of hyperuricaemia in adult patients at intermediate risk of Tumour Lysis Syndrome (TLS) in whom allopurinol is either unsuitable or contraindicated).

Horse ATG - FG1 390/15 - Formulary Group decision will be published by 6th July 2016. (Indication: for the treatment of aplastic anaemia).

Lenalidomide (Revlimid®) - SMC 1096/15 - Formulary Group decision will be published by 6th July 2016. (Indication: for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant).

Mepolizumab (Nucala®) - SMC 1149/16 Formulary Group decision will be published by 6th July 2016. (Indication: as an add-on treatment for severe refractory eosinophilic asthma in adult patients who have eosinophils of at least 150 cells per microlitre (0.15 x 109/L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids).

Naloxegol (Moventig®) - SMC 1106/15 - in progress. (Indication: for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s)).

Naproxen (Stirlescent®) - SMC 1154/16 - Formulary Group decision will be published by 6th July 2016. (Indication: for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults patients unable to swallow tablets).

Netupitant/palonosetron (Akynzeo®) - SMC 1109/15 - Formulary Group decision will be published by 6th July 2016. (Indication: in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy).

Netupitant/palonosetron (Akynzeo®) -  FG1 393/16 - Formulary Group decision will be published by 6th July 2016. (Indication: in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy).

Pembrolizumab (Keytruda®) - SMC 1086/15 Formulary Group decision will be published by 6th July 2016. (Indication: as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab).

Regorafenib (Stivarga®) - SMC 1031/15 - in progress. (Indication: for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib).

Ulipristal acetate (Esmya®) - SMC 1128/16 - in progress. (Indication: for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END